Lazinamo

Azelastine hydrochloride and fluticasone propionate, the active ingredients in Lazinamo, are an antihistamine and a corticosteroid presented as a nasal spray for nasal use. They treat allergic rhinitis, including seasonal and perennial forms, by reducing histamine‑mediated symptoms and nasal inflammation.

GNH USA supplies Lazinamo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lazinamo combines an antihistamine and a corticosteroid to address allergic airway inflammation. - Allergic rhinitis (seasonal): reduces sneezing, itching, and rhinorrhea associated with seasonal allergens. - Allergic rhinitis (perennial): alleviates chronic nasal congestion and discharge caused by year‑round allergens. - Nasal congestion due to allergic inflammation: decreases mucosal edema and improves airflow.

Lazinamo may cause local and systemic reactions typical of intranasal antihistamine‑corticosteroid combinations.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Bitter taste after administration - Mild epistaxis (nosebleed) - Throat irritation or cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or ocular pressure increase - Adrenal suppression with prolonged high‑dose use - Fungal sinusitis or secondary infection - Profound or persistent nosebleeds

Before using Lazinamo, consider the following safety measures. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Concomitant nasal surgery: postpone treatment until the surgical site has healed. - Pediatric use: follow pediatric guidance; safety not established for very young children. - Hypersensitivity: avoid if known allergy to azelastine, fluticasone, or any formulation components. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lazinamo can interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase fluticasone exposure. - Live vaccines: systemic corticosteroid effect may reduce vaccine efficacy. - MAO inhibitors: potential additive antihistamine effects.

Moderate Interactions (Monitor Closely): - Other intranasal decongestants: risk of increased nasal irritation. - Oral antihistamines: may enhance sedation. - Antifungal azoles: may affect fluticasone metabolism.